Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

NCT06560905 — Phase 2, Recruiting, 16 participants, Royal Marsden NHS Foundation Trust

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT06560905, acronym PPPIMS
Status	Recruiting
Phase	Phase 2
Study type	Interventional; na, single group, masking: none, diagnostic
Enrollment	16 (Estimated)
Sponsor	Royal Marsden NHS Foundation Trust (Other)
Conditions	Malignant Melanoma
Interventions	68Ga-PSMA (Drug)
Dates	start 2025-03-11, primary completion 2025-12-31 (estimated), completion 2025-12-31 (estimated), first posted 2024-08-19, last updated 2025-07-01
Locations	1 site in United Kingdom

-Summary

This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Expand all sections · Collapse all

+Detailed description

The proposed 'Preoperative Planning PSMA-PET in Melanoma Surgery (PPPIMS)' trial is a Phase 2 study, investigating the ability of PSMA as a biomarker to accurately detect melanoma metastases in patients with palpable lymphadenopathy and oligometastatic melanoma. If proven to have diagnostic utility, it may allow more precise 3D lymphatic mapping and identification of tumour in intricate anatomical areas, resulting in more accurate surgical planning. A more precise delineation of nodal disease and metastasis will result in a more accurate and lesser surgical dissection, and consequent reduction in morbidity.

The PSMA-PET-CT will be compared with the standard-of-care imaging, FDG-PET-CT to evaluate utility of this approach. It is of note that FDG-PET CT has a high background FDG uptake normally seen in the brain and liver, and PSMA could potentially be a more favourable tracer if there is less background uptake.

+Arms and interventions

Arm	Type	Interventions	Description
PSMA PET-CT	Experimental	Drug: 68Ga-PSMA	Within the two weeks prior to surgery, the patients will undergo both PSMA PET-CT \& FDG PET-CT scans at least 48 hours apart. The Investigational Medicinal Product (IMP) under investigation in this trial is 68Ga-PSMA. This is an imaging radionuclide tracer.

68Ga-PSMA (Drug): This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.

+Outcome measures

Primary outcomes

PSMA PET-CT detection of melanoma metastases [1 Year]: The principal objective of the study is to investigate whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using a PSMA PET/ CT.

Secondary outcomes

Compare FDG PET-CT & PSMA PET-CT [1 Year]: 1. To compare FDG PET-CT in identifying known metastasis with PSMA PET-CT 2. To compare the radiological information obtained by FDG PET-CT and PSMA PET-CT

+Eligibility

Sex: Male, ages: 18 Years to any

Inclusion Criteria:

* Males ≥18 years of age
* Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site

Exclusion Criteria:

* Patients unable to give voluntary written informed consent to participate in this study
* Patients not willing to complete all the study assessments
* Patients who are females
* Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists.
* Patients who have or have previously been diagnosed with prostate cancer
* Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning
* Patients not fluent in English

+Locations (1)

Facility	City	Country	Status
The Royal Marsden NHS Foundation Trust	London	United Kingdom	Recruiting

+Investigators

Myles Smith, Principal investigator, Royal Marsden NHS Foundation Trust